We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ALGN Stock to Gain From CE Mark Win for Invisalign Palatal Expander
Read MoreHide Full Article
Align Technologies (ALGN - Free Report) has received a CE Mark in Europe under the Medical Device Regulation (MDR 2017/745) for its Invisalign Palatal Expander System. The system has completed registration with MHRA for the United Kingdom and overseas territories.
The latest developments mark a milestone in the company’s efforts to enhance clinical outcomes and efficiency in orthodontics. Both approvals are for broad patient applicability, including growing children, teens and adults (with surgery or other techniques).
ALGN Stock's Potential Movement Following the News
ALGN shares finished at $223.87 yesterday and edged up 0.5% in the after-hours trading following the announcement. With the company actively commercializing its first direct 3D printed orthodontic appliance to more markets, we expect the latest development to boost market sentiment toward ALGN stock.
Align Technology has a market capitalization of $16.62 billion at present. Going by the Zacks Consensus Estimate, the company’s earnings are likely to increase 7.9% in 2024 on a 3.9% improvement in revenues. In the trailing four quarters, it delivered an earnings beat of 6.18%, on average.
Relevance of ALGN’s Invisalign Palatal Expander System
The Invisalign Palatal Expander System is a modern and innovative direct 3D printed device based on proprietary and patented technology. Invisalign Palatal Expanders are intended for rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw) with primary, mixed or permanent dentition during the treatment of patients.
The system consists of a series of removable devices staged in small increments of movement to expand a patient’s narrow maxilla to a position determined by their treating doctor. Each direct 3D printed device is customized to the patient’s unique anatomy based on an iTero intraoral digital scan. A palatal expansion treatment plan and device design are then developed using the company’s proprietary AI-driven orthodontic software.
Image Source: Zacks Investment Research
The Invisalign Palatal Expanders, along with Invisalign First aligners, offer a full early intervention treatment solution for Phase 1 treatment, an early interceptive orthodontic treatment in patients aged six through 10. The addition of mandibular advancement features to Invisalign aligners also provides doctors with more options for treating skeletal and dental jaw imbalances and bite correction for their growing patients during their teenage years.
Align Technology expects to commercially avail the System across the EMEA in the first quarter of 2025. At present, it is available in the United States, Canada, Australia, New Zealand, Hong Kong and Singapore.
Industry Prospects Favoring ALGN
Per a Research report, the global 3D printing market is valued at $3.1 billion in 2023 and is expected to witness a compound annual rate of 26.4% through 2030. 3D printing dentistry has established a strong position in today’s dental products due to the combination of state-of-the-art technology and a potential footprint.
Other Developments in ALGN
Last month, the company unveiled the next innovation of Invisalign Smile Architect software, now with Multiple Treatment Plans, allowing doctors to visually compare and modify orthodontic-only and ortho-restorative treatment plans side-by-side. The Multiple Treatment Plans are integrated into ClinCheck treatment planning software for doctors to visually compare, review and choose the best treatment option for each patient.
ALGN Stock Price Performance
In the past month, ALGN shares have risen 6.2% compared with the industry’s 4.9% growth.
ALGN’s Zacks Rank and Key Picks
Align Technologies currently carries a Zacks Rank #4 (Sell).
Penumbra’s shares have risen 16.4% in the past year. Estimates for the company’s 2024 earnings per share have jumped 8.1% to $2.79 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have jumped 0.4% to $4.59 in the past 30 days. Shares of the company have rallied 14% in the past year against the industry’s 0.7% fall. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
Estimates for Globus Medical’s 2024 earnings per share have increased 0.4% to $2.95 in the past 30 days. Shares of the company have surged 14% in the past year against the industry’s 4.1% fall. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%. In the last reported quarter, it delivered an earnings surprise of 27.69%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
ALGN Stock to Gain From CE Mark Win for Invisalign Palatal Expander
Align Technologies (ALGN - Free Report) has received a CE Mark in Europe under the Medical Device Regulation (MDR 2017/745) for its Invisalign Palatal Expander System. The system has completed registration with MHRA for the United Kingdom and overseas territories.
The latest developments mark a milestone in the company’s efforts to enhance clinical outcomes and efficiency in orthodontics. Both approvals are for broad patient applicability, including growing children, teens and adults (with surgery or other techniques).
ALGN Stock's Potential Movement Following the News
ALGN shares finished at $223.87 yesterday and edged up 0.5% in the after-hours trading following the announcement. With the company actively commercializing its first direct 3D printed orthodontic appliance to more markets, we expect the latest development to boost market sentiment toward ALGN stock.
Align Technology has a market capitalization of $16.62 billion at present. Going by the Zacks Consensus Estimate, the company’s earnings are likely to increase 7.9% in 2024 on a 3.9% improvement in revenues. In the trailing four quarters, it delivered an earnings beat of 6.18%, on average.
Relevance of ALGN’s Invisalign Palatal Expander System
The Invisalign Palatal Expander System is a modern and innovative direct 3D printed device based on proprietary and patented technology. Invisalign Palatal Expanders are intended for rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw) with primary, mixed or permanent dentition during the treatment of patients.
The system consists of a series of removable devices staged in small increments of movement to expand a patient’s narrow maxilla to a position determined by their treating doctor. Each direct 3D printed device is customized to the patient’s unique anatomy based on an iTero intraoral digital scan. A palatal expansion treatment plan and device design are then developed using the company’s proprietary AI-driven orthodontic software.
Image Source: Zacks Investment Research
The Invisalign Palatal Expanders, along with Invisalign First aligners, offer a full early intervention treatment solution for Phase 1 treatment, an early interceptive orthodontic treatment in patients aged six through 10. The addition of mandibular advancement features to Invisalign aligners also provides doctors with more options for treating skeletal and dental jaw imbalances and bite correction for their growing patients during their teenage years.
Align Technology expects to commercially avail the System across the EMEA in the first quarter of 2025. At present, it is available in the United States, Canada, Australia, New Zealand, Hong Kong and Singapore.
Industry Prospects Favoring ALGN
Per a Research report, the global 3D printing market is valued at $3.1 billion in 2023 and is expected to witness a compound annual rate of 26.4% through 2030. 3D printing dentistry has established a strong position in today’s dental products due to the combination of state-of-the-art technology and a potential footprint.
Other Developments in ALGN
Last month, the company unveiled the next innovation of Invisalign Smile Architect software, now with Multiple Treatment Plans, allowing doctors to visually compare and modify orthodontic-only and ortho-restorative treatment plans side-by-side. The Multiple Treatment Plans are integrated into ClinCheck treatment planning software for doctors to visually compare, review and choose the best treatment option for each patient.
ALGN Stock Price Performance
In the past month, ALGN shares have risen 6.2% compared with the industry’s 4.9% growth.
ALGN’s Zacks Rank and Key Picks
Align Technologies currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Penumbra (PEN - Free Report) , Haemonetics (HAE - Free Report) and Globus Medical (GMED - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Penumbra’s shares have risen 16.4% in the past year. Estimates for the company’s 2024 earnings per share have jumped 8.1% to $2.79 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have jumped 0.4% to $4.59 in the past 30 days. Shares of the company have rallied 14% in the past year against the industry’s 0.7% fall. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
Estimates for Globus Medical’s 2024 earnings per share have increased 0.4% to $2.95 in the past 30 days. Shares of the company have surged 14% in the past year against the industry’s 4.1% fall. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%. In the last reported quarter, it delivered an earnings surprise of 27.69%.